ArriVent's ARR-217 shows 44.8% response rate at 6 mg/kg in Phase 1 colorectal cancer trial
AVBP•ArriVent Biopharma reported a 44.8% response rate and 93.1% disease control among 29 heavily pretreated colorectal cancer patients receiving ARR-217 at 6 mg/kg every three weeks. Grade 3 or higher treatment-related adverse events affected 20.4% at that dose; further data are expected in 2027.
1. Phase 1 results
ArriVent Biopharma reported 13 responses among 29 patients receiving ARR-217 at 6 mg/kg every three weeks, a response rate of 44.8%. The responses included seven confirmed partial responses, four pending confirmation and two unconfirmed partial responses; disease control was 93.1%. Grade 3 or higher treatment-related adverse events affected 20.4% at the dose, and no treatment-related deaths or interstitial lung disease occurred across doses. ARR-217 advanced into Phase 1b dose optimization at 5 and 6 mg/kg every three weeks, with further data expected in 2027.
